Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis

Amyloid

Volumn 18, Issue 3, 2011, Pages 136-146

  Kluve Beckerman, Barbara ^a   Hardwick, Joyce ^a   Du, Lijing ^a   Benson, Merrill D ^a,b   Monia, Brett P ^c   Watt, Andrew ^c   Crooke, Rosanne M ^c   Mullick, Adam ^c  

^a INDIANA UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

AA amyloidosis; Antisense oligonucleotide; Mouse model; Serum amyloid A

Indexed keywords

AMYLOID A PROTEIN; ANTISENSE OLIGONUCLEOTIDE; AZO COMPOUND; AZOCASEIN; CYTOKINE; SERUM AMYLOID A; SILVER NITRATE; UNCLASSIFIED DRUG;

AMYLOID A AMYLOIDOSIS; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

AMYLOIDOSIS; ANIMALS; CASEINS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; OLIGONUCLEOTIDES, ANTISENSE; PLAQUE, AMYLOID; SERUM AMYLOID A PROTEIN; SILVER NITRATE;

EID: 80052224466     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2011.597464     Document Type: Article

References (43)

1. Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 1985;21:283-287. (Pubitemid 15108055)
2. Tape C, Tan R, Nesheim M, Kisilevsky R. Direct evidence for circulating apoSAA as the precursor of tissue AA amyloid deposits. Scand J Immunol 1988;28:317-324. (Pubitemid 18263218)
3. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-2371. (Pubitemid 46883770)
4. Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009;61:1435-1440.
5. van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005;5:87-98. (Pubitemid 41597267)
6. Verine J, Mourad N, Desseaux K, Vanhille P, NoLH, Beaufils H, Grateau G, et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 2007;38:1798-1809. (Pubitemid 350186043)
7. Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M. Amyloidosis as a cause of death in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:408-413. (Pubitemid 352003208)
8. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-29. (Pubitemid 32709735)
9. Ganapathi MK, Rzewnicki D, Samols D, Jiang SL, Kushner I. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol 1991;147:1261-1265.
10. Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P. The role of NFkappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem 1993;268:25624-25631.
11. Jiang SL, Lozanski G, Samols D, Kushner I. Induction of human serum amyloid A in Hep 3B cells by IL-6 and IL-1 beta involves both transcriptional and post-transcriptional mechanisms. J Immunol 1995;154:825-831.
12. Benditt EP, Eriksen N, Hanson RH. Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci USA 1979;76:4092-4096. (Pubitemid 9249030)
13. De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;2:231-234.
14. Rken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111-122. (Pubitemid 34169846)
15. Maury CP, Liljestr M, Laiho K, Tiitinen S, Kaarela K, Hurme M. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003;48:3068-3076. (Pubitemid 37409317)
16. Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, Yalnkaya F, et al.; International Study Group for Phenotype-Genotype Correlation in Familial Mediterranean Fever. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706-1712. (Pubitemid 46764102)
17. Maury CP, Aittoniemi J, Tiitinen S, Laiho K, Kaarela K, Hurme M. Variant mannose-binding lectin 2 genotype is a risk factor for reactive systemic amyloidosis in rheumatoid arthritis. J Intern Med 2007;262:466-469. (Pubitemid 47404366)
18. Westermark P, Westermark GT. Review. Reflections on amyloidosis in Papua New Guinea. Philos Trans R Soc Lond, B, Biol Sci 2008;363:3701-3705.
19. Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, Nishinarita M, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet 1999;105:360-366. (Pubitemid 29476289)
20. Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford) 2006;45:43-49. (Pubitemid 43033873)
21. Sipe JD, McAdam KP, Uchino F. Biochemical evidence for the biphasic development of experimental amyloidosis. Lab Invest 1978;38:110-114. (Pubitemid 8269744)
22. Kisilevsky R, Boudreau L. Kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy. Lab Invest 1983;48:53-59. (Pubitemid 13110934)
23. Skinner M, Shirahama T, Benson MD, Cohen AS. Murine amyloid protein AA in casein-induced experimental amyloidosis. Lab Invest 1977;36:420-427. (Pubitemid 8097896)
24. Kisilevsky R. Preparation and propagation of amyloid-enhancing factor. Methods Mol Biol 2005;299:237-241.
25. Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol 2008;18:109-118.
26. Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, et al.; Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349-2360. (Pubitemid 46883769)
27. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93-97.
28. Thomas T, Ginsberg H. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. Curr Atheroscler Rep 2010;12:58-65.
29. Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 2009;5:381-391.
30. Yamamoto K, Migita S. Complete primary structures of two major murine serum amyloid A proteins deduced from cDNA sequences. Proc Natl Acad Sci USA 1985;82:2915-2919. (Pubitemid 15097763)
31. Schger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 1987;166:368-379. (Pubitemid 18004907)
32. Westermark GT, Johnson KH, Westermark P. Staining methods for identification of amyloid in tissue. Meth Enzymol 1999;309:3-25. (Pubitemid 29446438)
33. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259-293.
34. Hatanaka E, Monteagudo PT, Marrocos MS, Campa A. Interaction between serum amyloid A and leukocytes - a possible role in the progression of vascular complications in diabetes. Immunol Lett 2007;108:160-166. (Pubitemid 46198961)
35. He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009;113:429-437.
36. Song C, Hsu K, Yamen E, Yan W, Fock J, Witting PK, Geczy CL, Freedman SB. Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 2009;207:374-383.
37. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA. Phase I trial of ISIS 104838, a 2-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 2002;303:1334-1343. (Pubitemid 35424421)
38. Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, et al. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 2009;15:708-713.
39. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009;27:4741-4746.
40. Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, Flaim JD, Su J, Yu R, Baker BF, Wedel MK, Kastelein JJ. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. Am J Coll Cardiol 2010;55:1611-1618..
41. Raab R, Sparano JA, Ocean AJ, Christos P, Ramirez M, Vinciguerra V, Kaubisch A. A phase 1 trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction and gastric carcinoma. Am J ClinOncol 2010;33:61-65.
42. Yu RZ, Zhang H, Geary RS, Graham M, Masarjian L, Lemonidis K, Crooke R, et al. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther 2001;296:388-395. (Pubitemid 32112464)
43. Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, Wedel MK, et al. Cross-species comparison of in vivo PK/ PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009;77:910-919.